Ovarian Cancer Clinical Trials

Trials for someone you care about with ovarian cancer.

Cancer

Recruiting Drug Device Behavioral Older adults Healthy volunteers

18 trials

Comparing INCB123667 with Investigator's choice of chemotherapy for ovarian cancer

Explore this study →

Sites in Montreal, Calgary and 3 more cities

Official title: Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Ovarian Cancer · Incyte Corporation

Testing Niraparib for ovarian neoplasms

Explore this study →

Sites in Kelowna, Montreal and 1 more city

RecruitingPHASE2

Official title: A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

Ovarian Neoplasms · GlaxoSmithKline

Comparing 6 approaches for ovarian cancer

Explore this study →

Sites in Montreal, Edmonton and 2 more cities

RecruitingPHASE1

Official title: Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Ovarian Cancer · AstraZeneca

Get them matched to the best-fit trials

Answer a few questions and we'll find the closest matches for ovarian cancer.

Testing BMS-986463 for high-grade serous ovarian carcinoma (HGSOC)

Explore this study →

Sites in Montreal, Toronto and 1 more city

RecruitingPHASE1

Official title: A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

High-grade Serous Ovarian Carcinoma (HGSOC) · Bristol-Myers Squibb

Comparing 3 approaches for ovarian cancer

Explore this study →

Sites in Montreal, Calgary and 3 more cities

RecruitingPHASE3

Official title: A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Ovarian Cancer · Merck Sharp & Dohme LLC

Comparing Minimally Invasive Surgery with Laparotomy for advanced ovarian carcinoma

Explore this study →

Sites in Calgary and Toronto

RecruitingPHASE3

Official title: Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

Advanced Ovarian Carcinoma · M.D. Anderson Cancer Center

Comparing 6 approaches for ovarian neoplasms

Explore this study →

Sites in Toronto, Calgary and 4 more cities

RecruitingPHASE3

Official title: A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Ovarian Neoplasms · Eli Lilly and Company

Comparing 4 approaches for epithelial ovarian cancer

Explore this study →

Sites in Montreal, Edmonton and 3 more cities

RecruitingPHASE3

Official title: AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

Epithelial Ovarian Cancer · AstraZeneca

Comparing 3 approaches for ovarian cancer

Explore this study →

Sites in Toronto, Kelowna and 2 more cities

RecruitingPHASE2

Official title: Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

Ovarian Cancer · Canadian Cancer Trials Group

Comparing 14 approaches for ovarian cancer recurrent

Explore this study →

2 sites in Montreal

RecruitingPHASE1

Official title: A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

Ovarian Cancer Recurrent · Merck Sharp & Dohme LLC

Comparing Sacituzumab tirumotecan with Bevacizumab for ovarian neoplasms

Explore this study →

Sites in Montreal and Chicoutimi

RecruitingPHASE3

Official title: A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Ovarian Neoplasms · Merck Sharp & Dohme LLC

Comparing 3 approaches for epithelial ovarian cancer

Explore this study →

Sites in Montreal, Toronto and 2 more cities

RecruitingPHASE2

Official title: CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

Epithelial Ovarian Cancer · TORL Biotherapeutics, LLC

Testing Estetrol/Drospirenone for ovarian endometrioma

Explore this study →

One site, in Montreal

RecruitingPHASE4

Official title: Estetrol/Drospirenone to Reduce the Average Size of Endometriomas

Ovarian Endometrioma · Andrew Zakhari

Comparing Mocertatug rezetecan with Paclitaxel for ovarian neoplasms

Explore this study →

2 sites in Montreal

RecruitingPHASE3

Official title: A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

Ovarian Neoplasms · GlaxoSmithKline

Testing Niraparib for ovarian cancer

Explore this study →

One site, in Toronto

RecruitingPHASE2

Official title: Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

Ovarian Cancer · Sunnybrook Health Sciences Centre

Comparing 6 approaches for ovarian cancer

Explore this study →

Sites in Montreal, Greenfield Park and 3 more cities

RecruitingPHASE2

Official title: Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Ovarian Cancer · Regeneron Pharmaceuticals

Comparing Azenosertib with Investigator's choice of Chemotherapy for ovarian cancer

Explore this study →

Sites in Montreal, Sherbrooke and 1 more city

RecruitingPHASE3

Official title: A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

Ovarian Cancer · K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Comparing avutometinib with Pegylated liposomal doxorubicin for low grade serous ovarian cancer

Explore this study →

Sites in Montreal, Toronto and 1 more city

RecruitingPHASE3

Official title: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Low Grade Serous Ovarian Cancer · Verastem, Inc.

Looking for the closest fit?

Get matched →

Get notified when a matching trial opens

We'll watch for Ovarian Cancer trials near you.

← Back to all conditions

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.